Detailed information on the price and purchasing channels of the Laos imitation Krazati

Adagrasiib (Krazati) is an oral targeted drug for KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). It is an innovative small molecule inhibitor. Its mechanism of action targets the KRAS G12C mutant protein and can inhibit the proliferation and survival signals of tumor cells, showing significant efficacy in patients with advanced or metastatic lung cancer.

In the Chinese market, adagrasib has not yet been officially launched, so patients cannot purchase it directly through domestic hospitals or pharmacies. If patients need to use the drug, they can only rely on foreign channels to obtain it. Compared with the price of the original drug in the United States, which is as high as hundreds of thousands of yuan, the financial burden is greater, so the Laotian generic version has become a more feasible option.

The price of the Laotian generic drug Adagrasibu is significantly lower than that of the original drug. The price per box is about more than 3,000 yuan. The ingredients of the drug are basically the same as those of the original drug and can achieve similar therapeutic effects. Patients can obtain drugs through formal overseas drug purchase channels, but they need to pay attention to the legality of the channels and the quality of the drugs to avoid purchasing fake and shoddy products.

During use, patients should first undergo KRAS G12C mutation testing to confirm the indications, and at the same time manage the dosage and course of treatment under the guidance of a professional doctor. During treatment, liver and kidney function and blood routine should be monitored regularly, and possible adverse reactions, such as fatigue, diarrhea or nausea, should be paid attention to to ensure the safety and effectiveness of the treatment.